trending Market Intelligence /marketintelligence/en/news-insights/trending/orqhteee_6n2gjo-wihb8w2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Strongbridge secures rights to paralysis drug in US

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Strongbridge secures rights to paralysis drug in US

Strongbridge Biopharma PLC acquired the U.S. rights to KEVEYIS from a unit of Taro Pharmaceutical Industries Ltd.

KEVEYIS was approved by the FDA in August 2015 to treat hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a group of rare hereditary disorders that cause potentially severe episodes of muscle weakness or paralysis.

The drug has orphan drug exclusivity status in the U.S. through Aug. 7, 2022.

Strongbridge will provide Taro with upfront and deferred payments of $8.5 million in two installments. Taro is eligible to get additional future payments, subject to the achievement of certain sales unit milestones.

Taro will continue to manufacture the drug for Strongbridge under an exclusive supply agreement at least for the period of its orphan exclusivity, subject to certain commercial terms and conditions, including minimum supply purchases.

Strongbridge plans to commercially launch the drug in the U.S. in April 2017.